Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional

A Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.

ClinicalTrials.gov ID: NCT00625833

Public ClinicalTrials.gov record NCT00625833. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind Placebo Controlled Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.

Study identification

NCT ID
NCT00625833
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
330 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • [S,S]-Reboxetine Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2007
Primary completion
Oct 31, 2008
Completion
Oct 31, 2008
Last update posted
Dec 12, 2019

2007 – 2008

United States locations

U.S. sites
32
U.S. states
16
U.S. cities
27
Facility City State ZIP Site status
Pfizer Investigational Site Anniston Alabama 36207
Pfizer Investigational Site Birmingham Alabama 35235
Pfizer Investigational Site Mission Viejo California 92691
Pfizer Investigational Site Denver Colorado 80209
Pfizer Investigational Site New Britain Connecticut 06050
Pfizer Investigational Site Waterbury Connecticut 06708
Pfizer Investigational Site Tampa Florida 33609
Pfizer Investigational Site Winter Haven Florida 33880
Pfizer Investigational Site Lexington Kentucky 40503
Pfizer Investigational Site Louisville Kentucky 40213
Pfizer Investigational Site North Dartmouth Massachusetts 02747
Pfizer Investigational Site Jackson Mississippi 39202
Pfizer Investigational Site Tupelo Mississippi 38801
Pfizer Investigational Site Marionville Missouri 65705
Pfizer Investigational Site Springfield Missouri 65807
Pfizer Investigational Site Elizabeth New Jersey 07207
Pfizer Investigational Site Hamilton New Jersey 08690
Pfizer Investigational Site Buffalo New York 14209
Pfizer Investigational Site New York New York 10021
Pfizer Investigational Site New York New York 10024
Pfizer Investigational Site Cranston Rhode Island 02920
Pfizer Investigational Site Cumberland Rhode Island 02864
Pfizer Investigational Site Myrtle Beach South Carolina 29572
Pfizer Investigational Site Bartlett Tennessee 38133
Pfizer Investigational Site Beaumont Texas 77701
Pfizer Investigational Site Beaumont Texas 77706
Pfizer Investigational Site Dallas Texas 75230
Pfizer Investigational Site Dallas Texas 75246
Pfizer Investigational Site Dallas Texas 75390-8858
Pfizer Investigational Site Houston Texas 77079
Pfizer Investigational Site Houston Texas 77081
Pfizer Investigational Site Milwaukee Wisconsin 53209

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00625833, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 12, 2019 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00625833 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →